Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Clinical trials with endothelin receptor antagonists: what went wrong and where can we improve?

Kohan DE, Cleland JG, Rubin LJ, Theodorescu D, Barton M.

Life Sci. 2012 Oct 15;91(13-14):528-39. doi: 10.1016/j.lfs.2012.07.034. Epub 2012 Aug 6. Review.

2.

Endothelin antagonists in clinical trials: lessons learned.

Barton M, Kohan DE.

Contrib Nephrol. 2011;172:255-60. doi: 10.1159/000328859. Epub 2011 Aug 30.

PMID:
21894005
3.

Endothelin receptor antagonists.

Motte S, McEntee K, Naeije R.

Pharmacol Ther. 2006 Jun;110(3):386-414. Epub 2005 Oct 10. Review.

PMID:
16219361
4.

Endothelin receptor antagonists for pulmonary arterial hypertension.

Liu C, Chen J, Gao Y, Deng B, Liu K.

Cochrane Database Syst Rev. 2013 Feb 28;(2):CD004434. doi: 10.1002/14651858.CD004434.pub5. Review.

PMID:
23450552
5.

Endothelin.

Kawanabe Y, Nauli SM.

Cell Mol Life Sci. 2011 Jan;68(2):195-203. doi: 10.1007/s00018-010-0518-0. Epub 2010 Sep 17. Review.

6.

Endothelin receptor antagonists for pulmonary arterial hypertension.

Liu C, Chen J.

Cochrane Database Syst Rev. 2006 Jul 19;(3):CD004434. Review. Update in: Cochrane Database Syst Rev. 2009;(3):CD004434.

PMID:
16856046
7.

Current state of endothelin receptor antagonism in hypertension and pulmonary hypertension.

Miyagawa K, Emoto N.

Ther Adv Cardiovasc Dis. 2014 Oct;8(5):202-16. doi: 10.1177/1753944714541511. Epub 2014 Jul 1. Review.

PMID:
24990369
8.

The Twelfth International Conference on Endothelin (ET-12), Cambridge 2011.

Barton M, Davenport AP.

Life Sci. 2012 Oct 15;91(13-14):462-5. doi: 10.1016/j.lfs.2012.07.015. Epub 2012 Jul 26.

9.

Endothelin receptor antagonists: current status and perspectives.

Clozel M.

J Cardiovasc Pharmacol. 2000;35(4 Suppl 2):S65-68. Review.

PMID:
10976785
10.

Endothelin-Receptor Antagonists beyond Pulmonary Arterial Hypertension: Cancer and Fibrosis.

Aubert JD, Juillerat-Jeanneret L.

J Med Chem. 2016 Sep 22;59(18):8168-88. doi: 10.1021/acs.jmedchem.5b01781. Epub 2016 Jun 15. Review.

PMID:
27266371
11.

Endothelin receptor antagonists for pulmonary arterial hypertension.

Liu C, Chen J, Gao Y, Deng B, Liu K.

Cochrane Database Syst Rev. 2009 Jul 8;(3):CD004434. doi: 10.1002/14651858.CD004434.pub4. Review. Update in: Cochrane Database Syst Rev. 2013;2:CD004434.

PMID:
19588356
12.
13.

[Bosentan for treatment of heart failure].

Yoshimoto T, Hirata Y.

Nihon Rinsho. 2007 May 28;65 Suppl 5:159-63. Review. Japanese. No abstract available.

PMID:
17571378
14.

Pulmonary hypertension: current diagnosis and treatment.

Rosenkranz S.

Clin Res Cardiol. 2007 Aug;96(8):527-41. Epub 2007 Jun 4. Review.

PMID:
17534570
15.

Oral therapies for pulmonary arterial hypertension: endothelin receptor antagonists and phosphodiesterase-5 inhibitors.

Channick R, Preston I, Klinger JR.

Clin Chest Med. 2013 Dec;34(4):811-24. doi: 10.1016/j.ccm.2013.09.005. Review.

PMID:
24267306
16.

Endothelin receptor antagonists and cardiovascular diseases of aging.

Love MP, McMurray JJ.

Drugs Aging. 2001;18(6):425-40. Review.

PMID:
11419917
17.

[Emerging therapies for the treatment of pulmonary arterial hypertension].

Ghofrani HA, Voswinckel R, Reichenberger F, Grimminger F, Seeger W.

Herz. 2005 Jun;30(4):296-302. Review. German.

PMID:
15965806
18.

[Endothelin antagonists and their role in pharmacotherapy].

Dobrek Ł, Thor P.

Pol Merkur Lekarski. 2010 May;28(167):404-6. Review. Polish.

PMID:
20568407
19.

Endothelin receptor antagonists in pulmonary arterial hypertension.

Channick RN, Sitbon O, Barst RJ, Manes A, Rubin LJ.

J Am Coll Cardiol. 2004 Jun 16;43(12 Suppl S):62S-67S. Review.

20.

The dilemma of drug development for heart failure: when is the time to initiate large clinical trials?

Massie BM.

J Card Fail. 2003 Oct;9(5):347-9. No abstract available.

PMID:
14583893

Supplemental Content

Support Center